The onset of the COVID 19 pandemic has illustrated the importance of the FDA's desired state of a "maximally efficient, agile, flexible pharmaceutical manufacturing sector". Continuous manufacturing has the potential to rapidly respond to changes in demand due to local or global changes. Speakers in this session will discuss how government agencies, pharmacopeial organizations, and industry are working to advance continuous manufacturing and the potential of this technology to respond to the current situation and future challenges.
Global Head and Executive Director, GRACS CMC Policy,
Merck & Co., Inc.